MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Consolidator ... Mass Market Scale-up, Global Reach, Public Capital
1) Consolidators: Life Science & Therapeutics Sector
*Consolidators: Therapeutics Sector
*Consolidators: Diabetes and Kidney Health Companies
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
Organization & Developments: Tandem Diabetes
Parents
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
Children
*Insulin pump that's stylish, discreet and easy to use
*Tandem is seeking a better way to manage the disease with wearble insulin pumps, which essentially make it so patients can get fast-acting insulin continuously using a catheter, instead of periodic injections
*The insulin pump is the first of its kind with a color touch screen and it's "slim as a smartphone" so it can be "worn comfortably on or under clothing, without bumps or bulges."
2012: A touch-screen insulin pump & GSK’s open clinical trial data top medical innovations this week
2012: San Diego Life Sciences Roundup: Tandem Diabetes (2012)
2014: Tandem generated total sales of $29 million in 2013, the first full year of commercial sales of its slim device
2016: NIH Trial Combining Technology_federaltelemedicine
2018; Tandem Diabetes: Beneath The Numbers, The Story Is More Impressive_seekingalpha.com
2018: Tandem Diabetes Investor Day: Pumping Out Profits Soon_seekingalpha.com
2019: Another Significant Milestone in the Diabetes Space
2019: Closed-loop artificial pancreas from Tandem, Dexcom aces Type 1 diabetes study
2019: IBD Stock Of The Day Flirts With A Breakout As It Takes On Medtronic_www.investors.com
2019: Tandem Diabetes: ADA Presentations Reaffirm Control-IQ Excellent Performance - Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
2019: Tandem Diabetes: Strong Business Trends Should Continue Due To Market Growth And Share Gains_seekingalpha.com
2019: Tandem Diabetes: The Pump Is Primed_seekingalpha.com
2019: Tandem_Interoperable automated glycemic controller receives De Novo clearance
2020: Abbott, Tandem seal deal to combine CGM, insulin delivery tech
2020: This Diabetes Stock Just Threw Down A Gauntlet — Can Rivals Catch Up?_www.investors.com
2020: This IBD Stock Of The Day Broke Out And Is Now Eyeing Profitability_www.investors.com
2022: Tandem Diabetes Care: Overpriced, Underdelivering_seekingalpha.com
2022: Tandem Diabetes Care: Undervalued Technology Leader_ seekingalpha.com
2023: ADA: Tandem strategy chief on the software, hardware updates that'll get late diabetes tech adopters off 'the sidelines'_fiercebiotech
2023: Tandem Diabetes Care: More Ozempic Roadkill_seekingalpha.com
2023: Tandem plots late 2023 launch of slimmed-down insulin pump, with Dexcom, Abbott CGM integrations
2024: Tandem Diabetes: Mobi's Surprise Sales Fail To Offset Flat Operating Margin
2024: Tandem Diabetes: Recurring Value Erosion, Not Right Point In Cycle To Own
2025: Tandem Diabetes Care: A Barbell Bet On A High-Stakes Turnaround
2025: Tandem Diabetes Q4 Earnings Review: I Don't Share The Market's Skepticism
Jumps
*Key People: Tandem Diabetes Care
Finance & Acquisitions:Tandem Diabetes